Janus Henderson Group PLC Buys 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Janus Henderson Group PLC raised its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 21.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,080,367 shares of the company's stock after acquiring an additional 368,908 shares during the quarter. Janus Henderson Group PLC owned approximately 5.56% of Entrada Therapeutics worth $36,011,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new position in Entrada Therapeutics in the 4th quarter worth $36,000. BNP Paribas Financial Markets bought a new position in shares of Entrada Therapeutics in the fourth quarter worth about $57,000. Virtus ETF Advisers LLC purchased a new position in shares of Entrada Therapeutics during the 4th quarter valued at about $68,000. AlphaQuest LLC bought a new position in shares of Entrada Therapeutics during the 4th quarter valued at approximately $70,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after acquiring an additional 4,811 shares during the period. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA traded up $0.10 during mid-day trading on Tuesday, reaching $8.11. The company's stock had a trading volume of 29,801 shares, compared to its average volume of 129,323. Entrada Therapeutics, Inc. has a 52 week low of $7.10 and a 52 week high of $21.79. The stock has a fifty day moving average of $8.87 and a two-hundred day moving average of $13.33. The firm has a market capitalization of $307.61 million, a PE ratio of 5.15 and a beta of 0.04.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The company had revenue of $8.75 million for the quarter, compared to analysts' expectations of $10.98 million. Analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.